B Cell Lymphoma - Explore the Science & Experts | ideXlab

Scan Science and Technology

Contact Leading Edge Experts & Companies

B Cell Lymphoma

The Experts below are selected from a list of 125391 Experts worldwide ranked by ideXlab platform

Wyndham H. Wilson – 1st expert on this subject based on the ideXlab platform

  • diffuse large B Cell Lymphoma treatment approaches in the molecular era
    Nature Reviews Clinical Oncology, 2014
    Co-Authors: Mark Roschewski, Louis M Staudt, Wyndham H. Wilson

    Abstract:

    Diffuse large BCell Lymphoma (DLBCL) is curaBle in advanced stages, But up to one-third of patients will ultimately fail to respond to initial therapy. As we have now entered the molecular era of defining DLBCL, the goal is to pinpoint driver mutations and pathway addictions within distinct molecular suBsets of DLBCL. This Review descriBes the current molecular understanding of DLBCL and discusses promising targeted approaches for each suBtype.

  • Diffuse large B Cell Lymphoma: molecular targeted therapy
    International Journal of Hematology, 2012
    Co-Authors: Mark Roschewski, Kieron Dunleavy, Wyndham H. Wilson

    Abstract:

    Diffuse large B Cell Lymphoma (DLBCL) is a Biologically heterogeneous disease and the most common suBtype of B Cell non-Hodgkin’s Lymphoma in the USA. Even though it is a curaBle Lymphoma in advanced stages, up to 40 % of patients eventually relapse or fail to achieve remission. Improved understanding of the Biologic complexity of DLBCL reveals a diverse range of oncogenic driver mutations and signaling pathways that are essential for growth and survival of malignant Cells. Since many of these signaling pathways can Be targeted By small-molecule inhiBitors, the therapy for DLBCL is currently undergoing a paradigm shift away from conventional chemotherapy and toward targeted agents that capitalize on an improved Biologic understanding of the suBsets with the highest risk of treatment failure. Participation in well-conducted and rationally designed clinical trials will Be essential to realize the potential of these targeted agents and realize the goal of improving overall outcomes in the most common B Cell Lymphoma in the world.

  • Gray Zone Lymphoma: Better Treated Like Hodgkin Lymphoma or Mediastinal Large BCell Lymphoma?
    Current Hematologic Malignancy Reports, 2012
    Co-Authors: Kieron Dunleavy, Stefania Pittaluga, Elaine S. Jaffe, Cliona Grant, Franziska C. Eberle, Wyndham H. Wilson

    Abstract:

    Although primary mediastinal large BCell Lymphoma (PMBL) and classic Hodgkin Lymphoma of the nodular sclerosis type (CHL-NS) are distinct diseases, they share several clinical characteristics and Biologic features. Given that, it is not surprising that there exist mediastinal Lymphomas that do not fit well into either category But have clinical and morphologic features overlapping and transitional Between PMBL and CHL-NS. The term mediastinal gray zone Lymphoma (MGZL) has Been used for these tumors, which are included in the World Health Organization classification as “BCell Lymphoma, unclassifiaBle, with features intermediate Between diffuse large BCell Lymphoma and classic Hodgkin Lymphoma.” Although several studies have evaluated different therapeutic strategies in PMBL and CHL-NS, there is a paucity of prospective experience treating MGZL, given its rarity and relatively recent recognition. Historically, diseases that today would Be categorized as MGZL were proBaBly called “anaplastic large-Cell Lymphoma Hodgkin-like,” and their outcome with standard approaches was poor, with short overall survivals. In this review—following a discussion of the Biology and clinical features of MGZL, and how they compare to PMBL and CHL-NS—we outline how the treatment of PMBL and CHL-NS has evolved in recent years, and how we Believe MGZL should Be approached therapeutically.

Kieron Dunleavy – 2nd expert on this subject based on the ideXlab platform

  • dose adjusted epoch rituximaB therapy in primary mediastinal B Cell Lymphoma
    The New England Journal of Medicine, 2013
    Co-Authors: Kieron Dunleavy, Stefania Pittaluga, Lauren S Maeda, Ranjana H Advani, Clara C Chen, Julie Hessler, Seth M Steinberg, Cliona Grant, George E Wright, Gaurav Varma

    Abstract:

    BackgroundPrimary mediastinal BCell Lymphoma is a distinct suBtype of diffuse large-BCell Lymphoma that is closely related to nodular sclerosing Hodgkin’s Lymphoma. Patients are usually young and present with large mediastinal masses. There is no standard treatment, But the inadequacy of immunochemotherapy alone has resulted in routine consolidation with mediastinal radiotherapy, which has potentially serious late effects. We aimed to develop a strategy that improves the rate of cure and oBviates the need for radiotherapy. MethodsWe conducted a single-group, phase 2, prospective study of infusional dose-adjusted etoposide, doxoruBicin, and cyclophosphamide with vincristine, prednisone, and rituximaB (DA-EPOCH-R) and filgrastim without radiotherapy in 51 patients with untreated primary mediastinal BCell Lymphoma. We used results from a retrospective study of DA-EPOCH-R from another center to independently verify the outcomes. ResultsThe patients had a median age of 30 years (range, 19 to 52) and a media…

  • Diffuse large B Cell Lymphoma: molecular targeted therapy
    International Journal of Hematology, 2012
    Co-Authors: Mark Roschewski, Kieron Dunleavy, Wyndham H. Wilson

    Abstract:

    Diffuse large B Cell Lymphoma (DLBCL) is a Biologically heterogeneous disease and the most common suBtype of B Cell non-Hodgkin’s Lymphoma in the USA. Even though it is a curaBle Lymphoma in advanced stages, up to 40 % of patients eventually relapse or fail to achieve remission. Improved understanding of the Biologic complexity of DLBCL reveals a diverse range of oncogenic driver mutations and signaling pathways that are essential for growth and survival of malignant Cells. Since many of these signaling pathways can Be targeted By small-molecule inhiBitors, the therapy for DLBCL is currently undergoing a paradigm shift away from conventional chemotherapy and toward targeted agents that capitalize on an improved Biologic understanding of the suBsets with the highest risk of treatment failure. Participation in well-conducted and rationally designed clinical trials will Be essential to realize the potential of these targeted agents and realize the goal of improving overall outcomes in the most common B Cell Lymphoma in the world.

  • Gray Zone Lymphoma: Better Treated Like Hodgkin Lymphoma or Mediastinal Large BCell Lymphoma?
    Current Hematologic Malignancy Reports, 2012
    Co-Authors: Kieron Dunleavy, Stefania Pittaluga, Elaine S. Jaffe, Cliona Grant, Franziska C. Eberle, Wyndham H. Wilson

    Abstract:

    Although primary mediastinal large BCell Lymphoma (PMBL) and classic Hodgkin Lymphoma of the nodular sclerosis type (CHL-NS) are distinct diseases, they share several clinical characteristics and Biologic features. Given that, it is not surprising that there exist mediastinal Lymphomas that do not fit well into either category But have clinical and morphologic features overlapping and transitional Between PMBL and CHL-NS. The term mediastinal gray zone Lymphoma (MGZL) has Been used for these tumors, which are included in the World Health Organization classification as “BCell Lymphoma, unclassifiaBle, with features intermediate Between diffuse large BCell Lymphoma and classic Hodgkin Lymphoma.” Although several studies have evaluated different therapeutic strategies in PMBL and CHL-NS, there is a paucity of prospective experience treating MGZL, given its rarity and relatively recent recognition. Historically, diseases that today would Be categorized as MGZL were proBaBly called “anaplastic large-Cell Lymphoma Hodgkin-like,” and their outcome with standard approaches was poor, with short overall survivals. In this review—following a discussion of the Biology and clinical features of MGZL, and how they compare to PMBL and CHL-NS—we outline how the treatment of PMBL and CHL-NS has evolved in recent years, and how we Believe MGZL should Be approached therapeutically.

George E Wright – 3rd expert on this subject based on the ideXlab platform

  • dose adjusted epoch rituximaB therapy in primary mediastinal B Cell Lymphoma
    The New England Journal of Medicine, 2013
    Co-Authors: Kieron Dunleavy, Stefania Pittaluga, Lauren S Maeda, Ranjana H Advani, Clara C Chen, Julie Hessler, Seth M Steinberg, Cliona Grant, George E Wright, Gaurav Varma

    Abstract:

    BackgroundPrimary mediastinal BCell Lymphoma is a distinct suBtype of diffuse large-BCell Lymphoma that is closely related to nodular sclerosing Hodgkin’s Lymphoma. Patients are usually young and present with large mediastinal masses. There is no standard treatment, But the inadequacy of immunochemotherapy alone has resulted in routine consolidation with mediastinal radiotherapy, which has potentially serious late effects. We aimed to develop a strategy that improves the rate of cure and oBviates the need for radiotherapy. MethodsWe conducted a single-group, phase 2, prospective study of infusional dose-adjusted etoposide, doxoruBicin, and cyclophosphamide with vincristine, prednisone, and rituximaB (DA-EPOCH-R) and filgrastim without radiotherapy in 51 patients with untreated primary mediastinal BCell Lymphoma. We used results from a retrospective study of DA-EPOCH-R from another center to independently verify the outcomes. ResultsThe patients had a median age of 30 years (range, 19 to 52) and a media…

  • molecular diagnosis of primary mediastinal B Cell Lymphoma identifies a clinically favoraBle suBgroup of diffuse large B Cell Lymphoma related to hodgkin Lymphoma
    Journal of Experimental Medicine, 2003
    Co-Authors: Andreas Rosenwald, Philippe Gaulard, George E Wright, Karen Leroy, Xinyou Yu, Randy D Gascoyne, Wing C Chan, Tong Zhao, Corinne Haioun, Timothy C Greiner

    Abstract:

    Using current diagnostic criteria, primary mediastinal B Cell Lymphoma (PMBL) cannot Be distinguished from other types of diffuse large B Cell Lymphoma (DLBCL) reliaBly. We used gene expression profiling to develop a more precise molecular diagnosis of PMBL. PMBL patients were consideraBly younger than other DLBCL patients, and their Lymphomas frequently involved other thoracic structures But not extrathoracic sites typical of other DLBCLs. PMBL patients had a relatively favoraBle clinical outcome, with a 5-yr survival rate of 64% compared with 46% for other DLBCL patients. Gene expression profiling strongly supported a relationship Between PMBL and Hodgkin Lymphoma: over one third of the genes that were more highly expressed in PMBL than in other DLBCLs were also characteristically expressed in Hodgkin Lymphoma Cells. PDL2, which encodes a regulator of T Cell activation, was the gene that Best discriminated PMBL from other DLBCLs and was also highly expressed in Hodgkin Lymphoma Cells. The genomic loci for PDL2 and several neighBoring genes were amplified in over half of the PMBLs and in Hodgkin Lymphoma Cell lines. The molecular diagnosis of PMBL should significantly aid in the development of therapies tailored to this clinically and pathogenetically distinctive suBgroup of DLBCL.

  • the use of molecular profiling to predict survival after chemotherapy for diffuse large B Cell Lymphoma
    The New England Journal of Medicine, 2002
    Co-Authors: Andreas Rosenwald, George E Wright, Randy D Gascoyne, Wing C Chan, Joseph M Connors, Elias Campo, Richard I Fisher, Konrad H Mullerhermelink, Erlend B Smeland

    Abstract:

    Background The survival of patients with diffuse large-BCell Lymphoma after chemotherapy is influenced By molecular features of the tumors. We used the gene-expression profiles of these Lymphomas to develop a molecular predictor of survival. Methods Biopsy samples of diffuse large-BCell Lymphoma from 240 patients were examined for gene expression with the use of DNA microarrays and analyzed for genomic aBnormalities. SuBgroups with distinctive gene-expression profiles were defined on the Basis of hierarchical clustering. A molecular predictor of risk was constructed with the use of genes with expression patterns that were associated with survival in a preliminary group of 160 patients and was then tested in a validation group of 80 patients. The accuracy of this predictor was compared with that of the international prognostic index. Results Three gene-expression suBgroups — germinal-center BCell–like, activated BCell–like, and type 3 diffuse large-BCell Lymphoma — were identified. Two common oncogeni…